Vaccine-Immunotherapy combo tested in Tough-to-Treat lung cancer
NCT ID NCT02823990
Summary
This study tested whether combining a cancer vaccine (TG4010) with an immunotherapy drug (nivolumab) could help control advanced non-small cell lung cancer in patients whose previous treatments had stopped working. The vaccine aims to train the immune system to recognize and attack cancer cells, while the immunotherapy drug helps remove barriers that prevent immune cells from fighting the cancer. Researchers enrolled 13 patients to see if this combination was safe and could shrink tumors or slow disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of California San Diego
San Diego, California, 92103, United States
Conditions
Explore the condition pages connected to this study.